Home Newsfeeds Morgan Stanley Maintains Equal-Weight on AirSculpt Technologies, Lowers Price Target to $6

Morgan Stanley Maintains Equal-Weight on AirSculpt Technologies, Lowers Price Target to $6

Morgan Stanley analyst Simeon Gutman maintains AirSculpt Technologies (NASDAQ:AIRS) with a Equal-Weight and lowers the price target from $7 to $6.

byBenzinga Newsdesk

January 17, 2023

1 minute read

Morgan Stanley analyst Simeon Gutman maintains AirSculpt Technologies (NASDAQ:AIRS) with a Equal-Weight and lowers the price target from $7 to $6.

$100 Invested In Marriott Intl 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

December 12, 1:04 PM

Marriott Intl (NASDAQ:MAR) has outperformed the market over the past 20 years by 4.43% on an annualized basis…

MAR

News

Parsons Charges Up Zero Emission Vehicle And Fleet Electrification Business

By Benzinga Newsdesk

October 26, 4:49 PM

Parsons Corporation (NYSE:PSN) is leveraging their qualifications as a provider of detailed design and transit planning services to guide transit agencies through new fleet electrification and zero emission vehicle (ZEV)

PSN

Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate

By Benzinga Newsdesk

August 9, 4:40 PM

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.19 by 47.37 percent. This is a 24.32 percent decrease over earnings of $0.37 per share from the same

EXEL

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris – Emerges As Winner

By Vandana Singh

October 3, 8:32 AM

Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,

NVO

Morgan Stanley Maintains Equal-Weight on AirSculpt Technologies, Lowers Price Target to $6

Related Posts

$100 Invested In Marriott Intl 20 Years Ago Would Be Worth This Much Today

Parsons Charges Up Zero Emission Vehicle And Fleet Electrification Business

Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris – Emerges As Winner